Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal Pancreatitis Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies
A Clinical Records Review Study of the Frequency and Severity of Acute Abdominal Pancreatitis Episodes Reported From LPLD Subjects Previously Recruited to Clinical Studies PREPARATION-02, CT-AMT-011-01 and CT-AMT-011-02
Sponsor: Amsterdam Molecular Therapeutics
This observational or N/A phase trial investigates Lipoprotein Lipase Deficiency and is currently ongoing. Amsterdam Molecular Therapeutics leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Unknown Status NA
Status: Enrolling By Invitation → Unknown Status
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation NA
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amsterdam Molecular Therapeutics
- The Clinical Trial Company
For direct contact, visit the study record on ClinicalTrials.gov .